Company / Capital Expenditures
BioMarin Pharmaceutical Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$103.0M
FY2025
5-year range
$85.4M / $121.0M
FY2021-FY2025
Trend
+20.6%
vs FY2024
Sector context
#20 of 194
Health Care
What the data says
Among 194 Health Care companies, BioMarin Pharmaceutical is in the top 10% for capital expenditures. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $103M.
Based on SEC 10-K filings.
$103M in FY2025 with a 5-year CAGR of -2.1%. Top quartile in the Health Care sector.
Improved from $97M to $103M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -5.2%
- 5-Year CAGR
- -2.1%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 194This company $103.0M Sector average $117.5M
▼
-12.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.1%, indicating a declining trend.
- In FY2025, capital expenditures increased 20.6% year-over-year.
- Ranks #20 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2017.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.0M | +20.6% |
| FY2024 | $85.4M | -11.7% |
| FY2023 | $96.7M | -20.1% |
| FY2022 | $121.0M | +26.6% |
| FY2021 | $95.6M | -16.4% |
| FY2020 | $114.3M | -21.2% |
| FY2019 | $145.0M | +0.3% |
| FY2018 | $144.6M | -27.4% |
| FY2017 | $199.2M | +34.3% |
| FY2016 | $148.4M | -34.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026